New Formulations of Propafenone to Treat Atrial Fibrillation

Inclusion Criteria

• •Inclusion:
• •1. History of atrial fibrillation
• •2. Greater than or equal to 18 years of age
• •3. Scheduled to undergo an atrial fibrillation ablation procedure
• •4. Able to provide written informed consent
• •Exclusion:
• •1. Long-standing persistent atrial fibrillation at the time of ablation (greater than 1 year of a continuous atrial fibrillation episode)
• •2. Is in atrial fibrillation or atrial flutter the morning of the ablation procedure
• •3. The presence of any of the following in a patient without a permanent pacemaker for implantable cardiac defibrillator
• •1. sick sinus syndrome indicated by the inability to previously tolerate an antiarrhythmic drug due to bradycardia
• •2. sinus bradycardia with a heart rate less than 50 beats per minute at the time of study drug administration
• •3. right bundle branch block, left bundle branch block, or bifascicular block
• •4. PR-interval \> 280ms, or history of 2nd or 3rd degree atrioventricular block
• •4. Concomitant use of CYP3A4 and CYP2D6 inhibitors
• •5. Previous surgical or catheter ablation for atrial fibrillation or Cox-Maze procedure
• •6. Amiodarone use within 3 months prior to enrollment
• •7. Antiarrhythmic drug (other than amiodarone) within 5 half-lives prior to atrial fibrillation ablation
• •8. Expected life span \< 1 year
• •9. Creatinine clearance \<30 mL/min
• •10. Reversible cause of atrial fibrillation (ie. thyrotoxicosis)
• •11. Unrevascularized coronary artery disease
• •12. Canadian class IV angina
• •13. Left ventricular ejection fraction \<40%
• •14. New York Heart Association Class III or IV symptoms
• •15. Previous heart transplantation
• •16. Planned heart transplantation or ventricular assist device
• •17. Cardiac/thoracic surgery \<6 months prior to enrollment
• •18. Severe asthma or chronic obstructive pulmonary disease
• •19. Breastfeeding